Lilly’s September 15 announcement sets out planned presentations for the European Association for the Study of Diabetes meeting in Milan, September 28–October 2, 2026. As of this article’s publication, the meeting is still ahead.
What is on the programme
The company plans to present phase 3 retatrutide findings, including TRIUMPH-2, and phase 2 results for eloraTZP, an investigational combination of eloralintide and tirzepatide. Its programme also includes Foundayo (orforglipron) and Mounjaro research.
The release schedules the retatrutide and eloraTZP symposia for September 30. These are announced presentation plans, rather than our reporting from a completed conference.
Sources: Eli Lilly — company announcement
How to read a conference preview
A programme tells you which questions researchers will address. It does not guarantee that a presentation will answer every question about a drug. Our editorial focus is on whether the talk supplies enough detail to interpret the benefit alongside tolerability and treatment discontinuation.
Keep a preview, an abstract, a slide presentation, and a full journal paper separate in your notes. They may concern the same trial while offering very different amounts of information. A promotional summary may omit a result that appears prominently in the full tables.
Questions worth taking to the results
- Who was enrolled, and which important patient groups were excluded?
- Was the comparator placebo or an active treatment?
- How were people who stopped treatment handled in the analysis?
- What were the adverse events and discontinuation rates?
- Were the reported endpoints planned in advance?
These questions apply to both promising and disappointing findings. They help keep interpretation consistent, rather than changing the standard according to which medicine looks strongest.
Where approval fits
Clinical research and regulatory review are separate stages. A conference appearance, a successful phase 3 study, or a planned submission should not be described as an approval. Check the current regulator record when evaluating access claims.
Sources: U.S. FDA
Conclusion
The next useful step is the actual presentation and supporting report. This preview identifies what to watch without turning scheduled findings into completed events.